Kiromic BioPharma soars as cancer vaccine shows promise

Kiromic Biopharma

25/10/2021 12:34

** Shares of gene therapy company  KRBP.O  surge 48%
premarket to $2.84, set to open at three-week high 
    ** Says in combination with chemotherapy, co's cell therapy
cancer vaccine candidate - KiroVax/BSK01, demonstrated a
significant progression free survival benefit of 7 months in a
patient with metastatic pancreatic cancer  urn:newsml:reuters.com:*:nFWN2RL168
    ** The experimental vaccine was studied in a pilot
early-stage trial
    ** Shares set for their best session ever
    ** "We expect to be able to also progress Kiromic's CAR-T
therapies to the clinical arena" - KRBP CEO Maurizio Chiriva-
Internati
    ** Chimeric antigen receptor T cells (CAR-T) are T cells
that have been genetically engineered to produce an artificial T
cell receptor for use in immunotherapy
    ** KRBP down 77% YTD, and ~84% since debuting a year ago 

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))